Fecal Microbiota Transplantation for Liver Failure
ConditionLiver Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNingbo Medical Center Lihuili Hospital
About this trial
To investigate the safety, adverse reactions and therapeutic effects of fecal microbiota transplantation on patients with liver failure;to investigate the effect of fecal microbiota transplantation on the intestinal microecology and "gut-liver axis immune system" of liver failure, and further optimization of fecal microbiota transplantation technology.
Eligibility criteria
Qualifiers
Patients willing to sign informed consent
Patients aged 18-65
According to the diagnosis standard of liver failure in the guide for diagnosis and treatment of liver failure (2018 Edition), the eligible patients are included, that is, on the basis of chronic liver disease, the syndrome with acute jaundice deepening and coagulation dysfunction as the manifestation of liver failure caused by various inducements can be combined with complications such as Hepatoencephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome, etc And extrahepatic organ failure. The patient's jaundice deepened rapidly, the serum TBIL ≥ 10 × ULN or the daily rise ≥ 17.1 μ mol / L; there was bleeding, PTA ≤ 40% (or INR ≥ 1.5)
Disqualifiers
Patients with severe heart failure, COPD, cerebrovascular accident, nephrotic syndrome, etc;
Patients with gastrointestinal bleeding, pulmonary infection, septicemia, etc
Patients with liver cancer, lung cancer, lymphoma and other malignant tumors
Patients taking anticoagulants, mental diseases and immune diseases for a long time
Trial design
Treatments tested in this trial
- fecal microbiota transplantation
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov